AMAG Pharmaceuticals Provides Outlook

(RTTNews) - AMAG Pharmaceuticals, Inc. (AMAG) Sunday issued revenue outlook for the full year 2014 and 2015.

AMAG expects fourth-quarter revenues of $52.8 million to $54.5 million. This includes about $6.0 million of revenue recognized from AMAG's collaboration agreement with Takeda Pharmaceutical Co. Ltd. for commercialization of Feraheme outside of the U.S., which was mutually terminated in December 2014.

Fourth-quarter net product sales is expected to be between $47.2 million and $48.2 million, including between $23.8 million and $24.3 million of sales from Feraheme in the U.S. and between $23.1 million and $23.6 million of sales from Makena.

Analysts polled by Thomson Reuters currently estimate revenues of $35.64 million for the quarter. Analysts' estimates typically exclude one-time items.

For the full year 2014, the company expects revenues of $123.8 mln to $125.5 mln, including $14.0 mln revenue from collaboration agreement with Takeda.

Analysts currently estimate revenues of $106.59 mln for the 2014.

Net product sales is expected to be between $110.1 million and $111.1 million. U.S. Feraheme net sales are expected to be between $85.8 million and $86.3 million and Makena sales are expected to be between $23.1 million and $23.6 million.

For the full year 2015, the company expects revenue of between $380 million and $420 million, including product sales of $335 million to $375 million.

Analysts currently estimate revenues of $367.50 million for 2015.